Bio-Techne Corp Market Cap ($11.33 Billion)
Market Cap & Net Worth: Bio-Techne Corp (TECH)
Bio-Techne Corp market cap. Bio-Techne Corp (NASDAQ:TECH) has a market capitalization of $11.33 Billion ($11.33 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1972 globally and #750 in its home market, demonstrating a 0.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bio-Techne Corp's stock price $72.66 by its total outstanding shares 156818238 (156.82 Million). Also see TECH cash flow conversion for how efficiently the company converts equity into cash flow.
Bio-Techne Corp Market Cap History (2015–2026)
Bio-Techne Corp market cap history from 2015 to 2026. Data shows growth from $3.31 Billion to $11.39 Billion (11.23% CAGR). Check Bio-Techne Corp (TECH) share price today for real-time trading data and today's change.
Index Memberships
Bio-Techne Corp is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 0.99% | #13 of 39 |
|
S&P 500 Index
GSPC
|
$61.47 Trillion | 0.02% | #445 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.43% | #38 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.03% | #226 of 3165 |
Weight: Bio-Techne Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bio-Techne Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bio-Techne Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore TECH year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
9.38x
Bio-Techne Corp's market cap is 9.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
62.65x
Bio-Techne Corp's market cap is 62.65 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $4.89 Billion | $563.00 Million | $77.29 Million | 8.68x | 63.23x |
| 2018 | $5.50 Billion | $642.99 Million | $125.35 Million | 8.56x | 43.90x |
| 2019 | $8.40 Billion | $714.01 Million | $96.07 Million | 11.77x | 87.45x |
| 2020 | $12.22 Billion | $738.69 Million | $229.30 Million | 16.54x | 53.27x |
| 2021 | $19.96 Billion | $931.03 Million | $140.41 Million | 21.44x | 142.15x |
| 2022 | $12.88 Billion | $1.11 Billion | $272.05 Million | 11.65x | 47.36x |
| 2023 | $12.05 Billion | $1.14 Billion | $285.26 Million | 10.60x | 42.24x |
| 2024 | $11.30 Billion | $1.16 Billion | $168.10 Million | 9.75x | 67.19x |
| 2025 | $9.22 Billion | $1.22 Billion | $73.40 Million | 7.56x | 125.65x |
| 2026 | $11.39 Billion | $1.22 Billion | $181.86 Million | 9.38x | 62.65x |
Competitor Companies of TECH by Market Capitalization
Companies near Bio-Techne Corp in the global market cap rankings as of November 1, 2026. Also see total assets of Bio-Techne Corp for a full breakdown of the balance sheet.
Key companies related to Bio-Techne Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Bio-Techne Corp (2015–2026)
Market capitalization of Bio-Techne Corp from 2015 to today. Between 2015 and today, Bio-Techne Corp's market cap moved from $3.31 Billion to $ 11.39 Billion, with a yearly change of 11.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.39 Billion | +23.55% |
| 2025 | $9.22 Billion | -18.35% |
| 2024 | $11.30 Billion | -6.25% |
| 2023 | $12.05 Billion | -6.49% |
| 2022 | $12.88 Billion | -35.45% |
| 2021 | $19.96 Billion | +63.40% |
| 2020 | $12.22 Billion | +45.40% |
| 2019 | $8.40 Billion | +52.67% |
| 2018 | $5.50 Billion | +12.60% |
| 2017 | $4.89 Billion | +27.40% |
| 2016 | $3.84 Billion | +15.77% |
| 2015 | $3.31 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Bio-Techne Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.33 Billion USD |
| MoneyControl | $11.33 Billion USD |
| MarketWatch | $11.33 Billion USD |
| marketcap.company | $11.33 Billion USD |
| Reuters | $11.33 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of l… Read more